HBM Holdings Subsidiary, HBM Shanghai, Backs NK Cell-Tech's A+++ Financing Round

Reuters07-09

HBM Holdings Subsidiary, HBM Shanghai, Backs NK Cell-Tech's A+++ Financing Round

HBM Holdings Ltd.'s subsidiary, Harbour BioMed (Shanghai) Technology Development Co., Ltd, has played a significant role as a co-founder in NK Cell-Tech, a biotech company specializing in innovative NK cell therapy technology. Through its investment, HBM Shanghai holds a 10.90% equity interest in NK Cell-Tech. Recently, NK Cell-Tech successfully completed its A+++ round of financing, securing nearly RMB100 million from investors. This capital infusion will be directed towards advancing clinical trials of NK cell therapy product candidates and expanding the company's product pipeline. The financing underscores investor confidence in NK Cell-Tech's pioneering immunotherapy platform and provides essential support for its ongoing clinical and translational advancements.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HBM Holdings Ltd. published the original content used to generate this news brief on July 09, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2550337659?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-09 22:59","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2550337659","market":"us","top_or_hot":-1,"title":"HBM Holdings Subsidiary, HBM Shanghai, Backs NK Cell-Tech's A+++ Financing Round","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      HBM Holdings Subsidiary, HBM Shanghai, Backs NK Cell-Tech's A+++ Financing Round\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        HBM Holdings Ltd.'s subsidiary, Harbour BioMed (Shanghai) Technology Development Co., Ltd, has played a significant role as a co-founder in NK Cell-Tech, a biotech company specializing in innovative NK cell therapy technology. Through its investment, HBM Shanghai holds a 10.90% equity interest in NK Cell-Tech. Recently, NK Cell-Tech successfully completed its A+++ round of financing, securing nearly RMB100 million from investors. This capital infusion will be directed towards advancing clinical trials of NK cell therapy product candidates and expanding the company's product pipeline. The financing underscores investor confidence in NK Cell-Tech's pioneering immunotherapy platform and provides essential support for its ongoing clinical and translational advancements.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HBM Holdings Ltd. published the original content used to generate this news brief on July 09, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HBM Holdings Subsidiary, HBM Shanghai, Backs NK Cell-Tech's A+++ Financing Round</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHBM Holdings Subsidiary, HBM Shanghai, Backs NK Cell-Tech's A+++ Financing Round\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-07-09 22:59</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      HBM Holdings Subsidiary, HBM Shanghai, Backs NK Cell-Tech's A+++ Financing Round\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        HBM Holdings Ltd.'s subsidiary, Harbour BioMed (Shanghai) Technology Development Co., Ltd, has played a significant role as a co-founder in NK Cell-Tech, a biotech company specializing in innovative NK cell therapy technology. Through its investment, HBM Shanghai holds a 10.90% equity interest in NK Cell-Tech. Recently, NK Cell-Tech successfully completed its A+++ round of financing, securing nearly RMB100 million from investors. This capital infusion will be directed towards advancing clinical trials of NK cell therapy product candidates and expanding the company's product pipeline. The financing underscores investor confidence in NK Cell-Tech's pioneering immunotherapy platform and provides essential support for its ongoing clinical and translational advancements.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HBM Holdings Ltd. published the original content used to generate this news brief on July 09, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0209","symbol_name":"零售","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250709:nNDL5MYQD8:1","article_id":"2550337659","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2550337659","pubTimestamp":1752073198,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"HBM Holdings Ltd.'s subsidiary, Harbour BioMed  Technology Development Co., Ltd, has played a significant role as a co-founder in NK Cell-Tech, a biotech company specializing in innovative NK cell therapy technology. Through its investment, HBM Shanghai holds a 10.90% equity interest in NK Cell-Tech. Recently, NK Cell-Tech successfully completed its A+++ round of financing, securing nearly RMB100 million from investors. This capital infusion will be directed towards advancing clinical trials of NK cell therapy product candidates and expanding the company's product pipeline. The financing underscores investor confidence in NK Cell-Tech's pioneering immunotherapy platform and provides essential support for its ongoing clinical and translational advancements.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600539":"狮头股份","BK0209":"零售","BK0210":"商务服务","BK1161":"生物科技","BK1574":"生物医药B类股","02142":"和铂医药-B","BK0004":"股权转让","BK1583":"高瓴概念"},"translate_title":"HBM控股子公司HBM上海支持NK Cell-Tech的A+++轮融资","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600539":0.9,"02142":0.9},"content_text":"HBM Holdings Subsidiary, HBM Shanghai, Backs NK Cell-Tech's A+++ Financing Round\n    \n\n        HBM Holdings Ltd.'s subsidiary, Harbour BioMed (Shanghai) Technology Development Co., Ltd, has played a significant role as a co-founder in NK Cell-Tech, a biotech company specializing in innovative NK cell therapy technology. Through its investment, HBM Shanghai holds a 10.90% equity interest in NK Cell-Tech. Recently, NK Cell-Tech successfully completed its A+++ round of financing, securing nearly RMB100 million from investors. This capital infusion will be directed towards advancing clinical trials of NK cell therapy product candidates and expanding the company's product pipeline. The financing underscores investor confidence in NK Cell-Tech's pioneering immunotherapy platform and provides essential support for its ongoing clinical and translational advancements.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HBM Holdings Ltd. published the original content used to generate this news brief on July 09, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2550337659","isCrawlerRequest":true}